Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ciphergen Biosystems(CIPH): -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (327)	4/19/2005 1:59:56 PM
From: tuck	Read Replies (1) \| Respond to of 510

CIPH finally issues PR for AACR: vague fluff; no numbers at all. Doesn't talk about the so-called validation study, nor the reproducubility issues, nor even the relatively promising 3 year chinese study. In past years they'd talk of sensitivity and specificity with actual numbers for those parameters. We've seen only incremental improvement since, so I guess that's not worth touting any more. >>FREMONT, Calif., April 18 /PRNewswire-FirstCall/ -- Ciphergen Biosystems, Inc. (Nasdaq: CIPH - News) announced today that 44 studies involving its proprietary SELDI ProteinChip® Technology will be presented at the 96th Annual American Association of Cancer Research (AACR) conference in Anaheim, CA., April 16-20. Leading researchers are presenting biomarker discovery, validation, identification and assay development progress across a wide variety of cancers and therapeutic strategies enabled by the use of SELDI ProteinChip technology. Presentations made by Ciphergen's customers cover such fields as serum proteome profiling, metastasis prognosis, cancer therapeutics and monitoring drug response. Biomarker discovery and identification will be described for a broad range of cancer types including breast, colon, prostate, pancreatic, lung, head and neck, ovarian, and several other cancers. An example of the potential for Ciphergen's proprietary technology was demonstrated in a study from researchers at the University of Pittsburgh Cancer Institute titled, "Serum SELDI-TOF-MS Protein Profiling and Classification in Women with Estrogen Receptor Positive Breast Infiltrating Ductal Carcinoma." Using Ciphergen's SELDI ProteinChip technology including the CiphergenExpress and Biomarker Patterns Software for peak clustering and classification, researchers were able to discover protein biomarkers and produce an assay with good sensitivity and specificity that distinguishes a breast cancer population (n=48) from patients with benign breast lesions (n=47) and from healthy controls (n=48). Ciphergen Diagnostics, a division of Ciphergen Biosystems, Inc., is working with many of these leading researchers to translate their discoveries into clinically viable assay products that can be used to improve patient care. "This study and the many others that will be featured at AACR demonstrate the potential for improving patient care by discovering novel biomarkers and patterns of biomarkers and developing them into potential diagnostic and theranostic tests based on Ciphergen's SELDI ProteinChip® Technology," said William Rich, President & CEO of Ciphergen.<< snip Cheers, Tuck